This article is freely available to all

Article Abstract

Letter to the Editor

Sir: We thank Dr. Laird for his thoughtful comments about our article. This study was an open-label clinical trial with fluvoxamine used as a hepatic enzyme inhibitor, as clearly stated in our Method section. The problems associated with open-label studies are well known, as are the benefits and problems associated with double- and triple-blind studies.